vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and UNIVERSAL DISPLAY CORP \PA\ (OLED). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $142.2M, roughly 1.3× UNIVERSAL DISPLAY CORP \PA\). UNIVERSAL DISPLAY CORP \PA\ runs the higher net margin — 25.2% vs -0.7%, a 26.0% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -14.5%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -5.3%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
AVNS vs OLED — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $142.2M |
| Net Profit | $-1.3M | $35.9M |
| Gross Margin | 47.5% | 74.6% |
| Operating Margin | 1.4% | 30.1% |
| Net Margin | -0.7% | 25.2% |
| Revenue YoY | 0.7% | -14.5% |
| Net Profit YoY | 99.7% | -44.3% |
| EPS (diluted) | $-0.02 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $142.2M | ||
| Q4 25 | $180.9M | $172.9M | ||
| Q3 25 | $177.8M | $139.6M | ||
| Q2 25 | $175.0M | $171.8M | ||
| Q1 25 | $167.5M | $166.3M | ||
| Q4 24 | $179.6M | $162.3M | ||
| Q3 24 | $170.4M | $161.6M | ||
| Q2 24 | $171.7M | $158.5M |
| Q1 26 | — | $35.9M | ||
| Q4 25 | $-1.3M | $66.3M | ||
| Q3 25 | $-1.4M | $44.0M | ||
| Q2 25 | $-76.8M | $67.3M | ||
| Q1 25 | $6.6M | $64.4M | ||
| Q4 24 | $-397.3M | $46.0M | ||
| Q3 24 | $4.3M | $66.9M | ||
| Q2 24 | $1.8M | $52.3M |
| Q1 26 | — | 74.6% | ||
| Q4 25 | 47.5% | 76.1% | ||
| Q3 25 | 48.4% | 74.6% | ||
| Q2 25 | 52.6% | 77.2% | ||
| Q1 25 | 53.6% | 77.1% | ||
| Q4 24 | 54.6% | 77.0% | ||
| Q3 24 | 54.5% | 77.8% | ||
| Q2 24 | 55.7% | 75.8% |
| Q1 26 | — | 30.1% | ||
| Q4 25 | 1.4% | 38.9% | ||
| Q3 25 | 0.1% | 30.9% | ||
| Q2 25 | -42.6% | 39.9% | ||
| Q1 25 | 6.1% | 41.9% | ||
| Q4 24 | -233.0% | 32.3% | ||
| Q3 24 | 7.0% | 41.5% | ||
| Q2 24 | 3.7% | 35.6% |
| Q1 26 | — | 25.2% | ||
| Q4 25 | -0.7% | 38.4% | ||
| Q3 25 | -0.8% | 31.5% | ||
| Q2 25 | -43.9% | 39.2% | ||
| Q1 25 | 3.9% | 38.8% | ||
| Q4 24 | -221.2% | 28.4% | ||
| Q3 24 | 2.5% | 41.4% | ||
| Q2 24 | 1.0% | 33.0% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $-0.02 | $1.40 | ||
| Q3 25 | $-0.03 | $0.92 | ||
| Q2 25 | $-1.66 | $1.41 | ||
| Q1 25 | $0.14 | $1.35 | ||
| Q4 24 | $-8.64 | $0.96 | ||
| Q3 24 | $0.09 | $1.40 | ||
| Q2 24 | $0.04 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $516.4M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | — |
| Total Assets | $1.1B | $1.9B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $516.4M | ||
| Q4 25 | $89.8M | $602.4M | ||
| Q3 25 | $70.5M | $603.0M | ||
| Q2 25 | $90.3M | $525.2M | ||
| Q1 25 | $97.0M | $571.3M | ||
| Q4 24 | $107.7M | $492.7M | ||
| Q3 24 | $89.0M | $551.6M | ||
| Q2 24 | $92.2M | $530.5M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $778.2M | $1.8B | ||
| Q3 25 | $778.0M | $1.7B | ||
| Q2 25 | $776.3M | $1.7B | ||
| Q1 25 | $839.4M | $1.7B | ||
| Q4 24 | $828.5M | $1.6B | ||
| Q3 24 | $1.2B | $1.6B | ||
| Q2 24 | $1.2B | $1.5B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.1B | $1.9B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.1B | $1.9B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $1.7B | $1.8B | ||
| Q2 24 | $1.7B | $1.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $108.9M |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | 3.03× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $108.9M | ||
| Q4 25 | $28.2M | $31.1M | ||
| Q3 25 | $14.0M | $97.2M | ||
| Q2 25 | $6.8M | $51.9M | ||
| Q1 25 | $25.7M | $30.6M | ||
| Q4 24 | $57.9M | $34.7M | ||
| Q3 24 | $23.0M | $79.9M | ||
| Q2 24 | $27.8M | $67.0M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $15.1M | ||
| Q3 25 | $7.0M | $84.3M | ||
| Q2 25 | $-4.2M | $37.5M | ||
| Q1 25 | $19.0M | $17.5M | ||
| Q4 24 | $53.1M | $22.0M | ||
| Q3 24 | $20.0M | $66.2M | ||
| Q2 24 | $21.9M | $57.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 8.7% | ||
| Q3 25 | 3.9% | 60.4% | ||
| Q2 25 | -2.4% | 21.8% | ||
| Q1 25 | 11.3% | 10.5% | ||
| Q4 24 | 29.6% | 13.6% | ||
| Q3 24 | 11.7% | 41.0% | ||
| Q2 24 | 12.8% | 36.5% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 9.3% | ||
| Q3 25 | 3.9% | 9.2% | ||
| Q2 25 | 6.3% | 8.4% | ||
| Q1 25 | 4.0% | 7.9% | ||
| Q4 24 | 2.7% | 7.8% | ||
| Q3 24 | 1.8% | 8.4% | ||
| Q2 24 | 3.4% | 5.8% |
| Q1 26 | — | 3.03× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | 2.21× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 3.89× | 0.47× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | 5.35× | 1.19× | ||
| Q2 24 | 15.44× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
